The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
New facility is part of Aptar Pharma’s global expansion program
This acquisition marks Max Healthcare's entry into Lucknow
Express Scripts to add Zepbound to National Preferred Formulary
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The esteemed duo perfectly embody the brand's core values of family, love, and the special bond we share with our pets
Subscribe To Our Newsletter & Stay Updated
